- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03410420
Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study is designed to identify the level of tissue hypoxia in patients presenting with ascending aortic aneurysm. Ascending aortic aneurysms affect approximately 15,000 people in the United States each year, and represent a serious clinical problem because there is a known, but unspecified risk of aortic rupture or dissection. Despite progress made in the surgical management of ascending aortic aneurysms, the molecular and cellular mechanisms involved remain elusive. However, indirect evidence of tissue hypoxia have recently been described in the literature.
This pilot study will use pimonidazole-HCl, a compound that is retained by hypoxic cells and that has been used for detection of tissue hypoxia in human since the early 2000s. This pilot study will involve twenty patients who are candidates for aortic replacement due to aneurysm and twenty non-aneurysmal patients undergoing coronary artery bypass graft (controls). Patients will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time. During surgery, the resected aneurysmal aortic specimens (for patients undergoing aortic replacement) or aortic punch (for patients undergoing coronary artery bypass graft) will be harvested. Tissue hypoxia will be qualitatively and quantitatively assessed in the investigator's research laboratory. Based on previous toxicological animal studies and previous use in human studies, the anticipated risk of severe or serious side effect will be relatively minimal.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Baltimore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adults ≥ 18 years of age who require one of the following open surgery:
- Ascending thoracic aorta repair due to aneurysm;
- Aortic valve replacement due to aortic valve insufficiency;
- Coronary artery bypass graft procedure due to coronary heart disease. Imaging CT scans and echography defining the presence of ascending aortic aneurysm will be centrally reviewed prospectively to ensure adherence to subject inclusion criteria.
Adequate hematologic functions:
- White blood cells > 2500/µ;
- Platelets > 100,000/µL;
- Hemoglobin > 8 g/dl.
- Adequate renal functions: serum creatinine < 2.0 mg/dl.
- Adequate hepatic function: serum alkaline phosphatase, bilirubin, and serum glutamate oxaloacetate transaminase twice normal levels.
- If the subject or partner is of childbearing potential, he or she must be willing to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening and for a period of at least 16 weeks after procedure.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form, release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documentation.
- Female subjects of childbearing potential must have a negative serum pregnancy test at screening. human chorionic gonadotropin levels will be assessed for all women of childbearing years prior to the procedure.
Exclusion Criteria:
- Severe septicemia or severe infection in the 4 weeks prior to study entry;
- The subject has a baseline NIHSS > 1 or modified Rankin Scale > 1.
- Active participation in other research therapy for cardiovascular repair/regeneration;
- Pregnant or breastfeeding at time of screening;
- Cardiothoracic surgery within 30 days prior to screening;
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Non aneurysmal
Intervention: four non-aneurysmal patients undergoing coronary artery bypass graft or aortic valve replacement will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
|
administration of pimonidazole-HCl
|
Experimental: Aneurysmal
Intervention: four patients who are candidates for aortic replacement due to aneurysm will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
|
administration of pimonidazole-HCl
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection of pimonidazole-HCl in aortic specimens
Time Frame: < 1 week
|
Levels of pimonidazole-HCl will be quantified in aortic specimens from patients who were administered pimonidazole-HCl prior to surgery
|
< 1 week
|
Collaborators and Investigators
Investigators
- Principal Investigator: Thomas G Gleason, MD, University of Maryland, Baltimore
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO16050046
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Aneurysm, Thoracic
-
Cook Research IncorporatedCompletedDescending Thoracic Aortic AneurysmUnited States, Canada
-
Medtronic CardiovascularMedtronicTerminatedThoracic Aortic AneurysmsUnited States
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmsUnited States
-
Wuhan Asia Heart HospitalFu Wai Hospital, Beijing, ChinaCompletedDissection of Aorta, Thoracic | Aneurysm of Aorta, ThoracicChina
-
Duke Vascular, Inc.Unknown
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruitingThoracic Aortic AneurysmsBelgium
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmsUnited States, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedThoracic Aortic AneurysmFrance
-
W.L.Gore & AssociatesRecruitingThoracic Aortic Aneurysm | Abdominal Aortic AneurysmSpain, Denmark, Italy, Norway, Netherlands, Sweden
Clinical Trials on Pimonidazole hydrochloride
-
National Institute of Allergy and Infectious Diseases...International Tuberculosis Research CenterWithdrawnRefractory Pulmonary TuberculosisKorea, Republic of
-
University Health Network, TorontoCompletedPancreatic CancerCanada
-
Marius Gustav BredellUnknown
-
Yana NajjarRecruiting
-
University Health Network, TorontoActive, not recruiting
-
H. Lee Moffitt Cancer Center and Research InstituteVarian Medical SystemsWithdrawnPancreatic Cancer | Resectable Pancreatic CancerUnited States
-
University Health Network, TorontoRecruitingSquamous Cell Carcinoma of Head and NeckCanada
-
Institute of Cancer Research, United KingdomCompletedCancerUnited Kingdom
-
H. Lee Moffitt Cancer Center and Research InstituteWithdrawnMelanoma | Skin Cancer
-
University of Wisconsin, MadisonCompleted